Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure?

IF 2.6 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatic Medicine : Evidence and Research Pub Date : 2023-10-12 eCollection Date: 2023-01-01 DOI:10.2147/HMER.S371507

Nimy John, Brittney Ibrahim, Mark Ebaid, Sammy Saab

{"title":"Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure?","authors":"Nimy John, Brittney Ibrahim, Mark Ebaid, Sammy Saab","doi":"10.2147/HMER.S371507","DOIUrl":null,"url":null,"abstract":"Aim: Since 2019, the COVID-19 pandemic wreaked havoc all over the world. Early in the course of the pandemic, multiple hepatic manifestations of COVID-19 were noted. We aim to categorize hepatic dysfunction and its outcome in COVID-19 infection.Methods: This is a review article based on a literature search in PubMed and Medline databases for articles detailing short-term and long-term outcomes of COVID-19 related liver dysfunction.Results: The most common hepatic manifestation of COVID-19 was aspartate amino transferase (AST) predominant transaminase elevation. Transaminases improve once the COVID-19 infection resolves. In addition, COVID-19 cholangiopathy, autoimmune hepatitis associated COVID-19, and splanchnic venous thrombosis triggered by COVID-19 are other manifestations. Patients with preexisting liver disease, especially those with cirrhosis, have poor prognosis with COVID-19 infections compared to the general population. Elevations in liver tests were associated with severe COVID-19 infections. Patients with chronic liver disease have a higher risk of morbidity and mortality from COVID-19 infection. Among patients with chronic liver disease, decompensated liver cirrhosis, hepatocellular carcinoma and alcohol-associated liver disease were associated with an increased risk of severity and mortality from COVID-19 infection. Interactions between antiviral therapy for COVID-19 and hepatitis B/hepatitis C medications must be considered in patients with chronic viral hepatitis and COVID-19 infection. COVID-19 vaccination-related hepatic dysfunction has been reported.Conclusion: COVID-19 is here to stay. Hepatic dysfunction in COVID-19 signals severe COVID-19 infections. Patients with chronic liver disease have higher mortality from COVID-19 than general population. It is important to remember the lessons learned throughout the covid pandemic to take care of patients with COVID-19 now and in the future. Further studies are needed to document long-term outcomes in patients with COVID-19 who developed hepatic dysfunction.","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"15 ","pages":"185-193"},"PeriodicalIF":2.6000,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/39/hmer-15-185.PMC10578169.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Medicine : Evidence and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/HMER.S371507","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Since 2019, the COVID-19 pandemic wreaked havoc all over the world. Early in the course of the pandemic, multiple hepatic manifestations of COVID-19 were noted. We aim to categorize hepatic dysfunction and its outcome in COVID-19 infection.

Methods: This is a review article based on a literature search in PubMed and Medline databases for articles detailing short-term and long-term outcomes of COVID-19 related liver dysfunction.

Results: The most common hepatic manifestation of COVID-19 was aspartate amino transferase (AST) predominant transaminase elevation. Transaminases improve once the COVID-19 infection resolves. In addition, COVID-19 cholangiopathy, autoimmune hepatitis associated COVID-19, and splanchnic venous thrombosis triggered by COVID-19 are other manifestations. Patients with preexisting liver disease, especially those with cirrhosis, have poor prognosis with COVID-19 infections compared to the general population. Elevations in liver tests were associated with severe COVID-19 infections. Patients with chronic liver disease have a higher risk of morbidity and mortality from COVID-19 infection. Among patients with chronic liver disease, decompensated liver cirrhosis, hepatocellular carcinoma and alcohol-associated liver disease were associated with an increased risk of severity and mortality from COVID-19 infection. Interactions between antiviral therapy for COVID-19 and hepatitis B/hepatitis C medications must be considered in patients with chronic viral hepatitis and COVID-19 infection. COVID-19 vaccination-related hepatic dysfunction has been reported.

Conclusion: COVID-19 is here to stay. Hepatic dysfunction in COVID-19 signals severe COVID-19 infections. Patients with chronic liver disease have higher mortality from COVID-19 than general population. It is important to remember the lessons learned throughout the covid pandemic to take care of patients with COVID-19 now and in the future. Further studies are needed to document long-term outcomes in patients with COVID-19 who developed hepatic dysfunction.

查看原文本刊更多论文

严重急性呼吸系统综合征冠状病毒2型感染后肝功能障碍患者的预后：我们应该测量什么？

目标：自2019年以来，新冠肺炎疫情在世界各地肆虐。在大流行的早期，注意到新冠肺炎的多种肝脏表现。我们的目的是对新冠肺炎感染的肝功能障碍及其结果进行分类。方法：这是一篇综述文章，基于PubMed和Medline数据库中的文献检索，详细介绍了新冠肺炎相关肝功能障碍的短期和长期结果。结果：新冠肺炎最常见的肝脏表现是天冬氨酸氨基转移酶（AST）为主的转氨酶升高。一旦新冠肺炎感染消退，转氨酶就会改善。此外，新冠肺炎胆道病、自身免疫性肝炎相关的新冠肺炎和新冠肺炎引发的内脏静脉血栓形成也是其他表现。与普通人群相比，已有肝病的患者，尤其是肝硬化患者，感染新冠肺炎的预后较差。肝脏检查的升高与严重的新冠肺炎感染有关。慢性肝病患者感染新冠肺炎的发病率和死亡率较高。在慢性肝病患者中，失代偿性肝硬化、肝细胞癌和酒精相关性肝病与新冠肺炎感染的严重程度和死亡率增加相关。在慢性病毒性肝炎和新冠肺炎感染患者中，必须考虑新冠肺炎抗病毒治疗与乙型肝炎/丙型肝炎药物之间的相互作用。新冠肺炎疫苗接种相关的肝功能障碍已有报道。结论：新冠肺炎将持续存在。新冠肺炎肝功能不全是严重新冠肺炎感染的信号。慢性肝病患者死于新冠肺炎的死亡率高于普通人群。重要的是要记住在新冠肺炎大流行期间吸取的教训，以便现在和将来照顾新冠肺炎患者。需要进一步的研究来记录发生肝功能障碍的新冠肺炎患者的长期结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Medicine : Evidence and Research GASTROENTEROLOGY & HEPATOLOGY-

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease Investigation and treatment of hepatic disease Pharmacology of drugs used for the treatment of hepatic disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered. As of 1st April 2019, Hepatic Medicine: Evidence and Research will no longer consider meta-analyses for publication.